.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Citi
Healthtrust
Baxter
Boehringer Ingelheim
Fuji
Covington
Cerilliant
AstraZeneca
US Department of Justice

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 065226

« Back to Dashboard

NDA 065226 describes CEFAZOLIN SODIUM, which is a drug marketed by Abraxis Pharm, Acs Dobfar, Aurobindo Pharma, Bedford, Cephazone Pharma, Facta Farma, Fresenius Kabi Usa, Glaxosmithkline, Hikma Farmaceutica, Hospira Inc, Qilu Pharm Co Ltd, Samson Medcl, Sandoz, Steri Pharma, Teva Pharms, Watson Labs Inc, and West-ward Pharms Int, and is included in thirty-one NDAs. It is available from seventeen suppliers. Additional details are available on the CEFAZOLIN SODIUM profile page.

The generic ingredient in CEFAZOLIN SODIUM is cefazolin sodium. There are twenty-seven drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.

Summary for 065226

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 065226

Ingredient-typeCephalosporins

Medical Subject Heading (MeSH) Categories for 065226

Suppliers and Packaging for NDA: 065226

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CEFAZOLIN SODIUM cefazolin sodium INJECTABLE;INJECTION 065226 ANDA Hospira, Inc. 0409-0805 0409-0805-01 25 VIAL in 1 CARTON (0409-0805-01) > 3 mL in 1 VIAL (0409-0805-11)
CEFAZOLIN SODIUM cefazolin sodium INJECTABLE;INJECTION 065226 ANDA General Injectables & Vaccines, Inc 52584-023 52584-023-10 1 VIAL in 1 BAG (52584-023-10) > 3 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 500MG BASE/VIAL
Approval Date:Apr 21, 2005TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 1GM BASE/VIAL
Approval Date:Apr 21, 2005TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Department of Justice
Cerilliant
Queensland Health
Citi
Healthtrust
Baxter
US Army
McKinsey
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot